Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Types of RNA01:20

Types of RNA

5.7K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
5.7K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

4.8K
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
4.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epicardial Abnormalities and Mesenchymal/Hematopoietic Cell Expansion in Plakophilin 2-Null Mouse Embryonic Hearts.

Cells·2025
Same author

GATA4: orchestrating cardiac development and beyond.

Cardiovascular research·2025
Same author

Generation of the human iPSC line UNIPDi006-A from a patient with arrhythmogenic cardiomyopathy carrying the DSG2 c.1672C > T pathogenic variant.

Stem cell research·2025
Same author

Perspectives on Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for Cardiac Transcriptomics.

Frontiers in molecular medicine·2024
Same author

Grand challenges in molecular cardiology.

Frontiers in molecular medicine·2024
Same author

Extracellular vesicle transfer of lncRNA H19 splice variants to cardiac cells.

Molecular therapy. Nucleic acids·2024
Same journal

Blood biomarkers and atrial remodeling in patients at risk of atrial fibrillation.

Frontiers in molecular medicine·2026
Same journal

Editorial: Targeted cancer therapy through metabolic pathways.

Frontiers in molecular medicine·2026
Same journal

Mapping the future of medicine through digital twins.

Frontiers in molecular medicine·2026
Same journal

Sirtuin 1 is a key molecular link between cellular senescence and heart failure.

Frontiers in molecular medicine·2026
Same journal

Molecular mechanisms underlying psoriasis and depression: an integrated analysis using mendelian randomization, transcriptomics, and single-cell sequencing.

Frontiers in molecular medicine·2026
Same journal

HIF1α reinforces PPARγ-dependent metabolic rechanneling to support lipid accumulation in adipocytes.

Frontiers in molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.1K

Long Non-Coding RNAs in Cardiac Hypertrophy.

Nicolò Mangraviti1, Leon J De Windt1

  • 1Department of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.

Frontiers in Molecular Medicine
|August 1, 2024
PubMed
Summary
This summary is machine-generated.

Long non-coding RNAs (lncRNAs) show therapeutic potential for heart disease. Further research into cardiac lncRNA mechanisms could lead to novel treatments for conditions like cardiac hypertrophy.

Keywords:
cardiac hypertrophycircRNAsheartheart diseaselncRNA

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.7K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.3K

Related Experiment Videos

Last Updated: Jun 18, 2025

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.1K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.7K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.3K

Area of Science:

  • Cardiovascular Biology
  • Molecular Genetics
  • RNA Biology

Background:

  • Heart disease remains a significant medical challenge with limited therapeutic strategies.
  • Whole genome sequencing has revealed non-coding RNAs (ncRNAs) as key regulators of gene expression.
  • Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) offer potential for novel therapeutic interventions due to their regulatory functions.

Purpose of the Study:

  • To explore the biology of cardiac long non-coding RNAs (lncRNAs).
  • To review the evidence supporting the therapeutic benefits of lncRNAs in treating cardiac hypertrophy.
  • To identify challenges and future directions in exploiting lncRNAs for cardiovascular disease treatment.

Main Methods:

  • Review of existing literature on lncRNA function in cardiac biology.
  • Analysis of studies investigating the role of lncRNAs in cardiac hypertrophy.
  • Exploration of current methods for lncRNA identification and modulation.

Main Results:

  • lncRNAs play crucial roles in the development of cardiac hypertrophy and other cardiovascular diseases.
  • Experimental studies confirm the value of lncRNAs as therapeutic targets.
  • Despite challenges in identification and expression analysis, progress in lncRNA annotation is ongoing.

Conclusions:

  • Cardiac lncRNAs represent a promising area for developing new therapeutic approaches for heart disease.
  • Understanding lncRNA mechanisms of action is critical for their clinical application.
  • Further research is needed to refine methods for modulating lncRNA expression and harness their full therapeutic potential.